Cocrystal Pharma, Inc. (COCP)
NASDAQ: COCP · Real-Time Price · USD
0.9699
-0.0070 (-0.72%)
At close: Nov 19, 2026, 4:00 PM EST
0.9300
-0.0399 (-4.11%)
After-hours: Nov 19, 2026, 7:18 PM EST
Cocrystal Pharma Revenue
Cocrystal Pharma had revenue of $105.00K in the quarter ending September 30, 2026. That makes Cocrystal Pharma the 44,713th largest company in the world by revenue and 6,380th in the United States.
Revenue (ttm)
$435.00K
Revenue Growth
n/a
P/S Ratio
43.26
Revenue / Employee
$43,500
Employees
10
Market Cap
18.68M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 2.01M | -4.55M | -69.32% |
| Dec 31, 2019 | 6.56M | - | - |
| Dec 31, 2018 | - | - | - |
| Dec 31, 2017 | - | - | - |
| Dec 31, 2016 | - | - | - |
| Dec 31, 2015 | 78.00K | 69.00K | 766.67% |
| Dec 31, 2014 | 9.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | 12.61M | -2.65M | -17.36% |
| Dec 31, 2010 | 15.25M | - | - |
| Dec 31, 2009 | - | - | - |
| Dec 31, 2008 | - | - | - |
| Dec 31, 2007 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Cue Biopharma | 35.64M |
| BioStem Technologies | 31.75M |
| Celularity | 18.67M |
| Lipocine | 3.74M |
| BeyondSpring | 1.88M |
| IGC Pharma | 1.11M |
| CervoMed | 8.73K |
COCP News
- 4 days ago - Cocrystal Pharma reports Q3 EPS (20c), consensus (17c) - TheFly
- 4 days ago - Cocrystal Pharma Provides Business Update and Reports Third Quarter 2026 Financial Results - GlobeNewsWire
- 2 months ago - Cocrystal Pharma doses last subject in norovirus challenge study - TheFly
- 2 months ago - Cocrystal Pharma Announces Last Subject Dosed in Phase 1b Human Challenge Study Evaluating CDI-988 for Norovirus Prevention and Treatment - GlobeNewsWire
- 3 months ago - Cocrystal Pharma Appoints Carol Brosgart, MD to its Board of Directors - GlobeNewsWire
- 3 months ago - Cocrystal Pharma announces $5M investment from Opko Health - TheFly
- 3 months ago - Cocrystal Pharma announces $5M private placement with Opko Health - TheFly
- 3 months ago - Cocrystal Pharma Announces $5 Million Private Placement with OPKO Health - GlobeNewsWire